Broad Institute

APRIL 2, 2024

He is also a professor at Harvard Medical School and Massachusetts General Hospital. But scientists haven’t been able to target those connections with therapies in part because they lack a complete understanding of metabolic pathways in the gut.

Disease 145

Disease Medical Schools Hospitals DNA 145

Broad Institute

NOVEMBER 13, 2023

Doing so would guide treatment decisions, such as whether to continue therapy. "We Such a test could help physicians detect recurrences earlier, intervene sooner, and tailor therapy to each patient. Earlier this year, the Broad entered into an agreement with Exact Sciences to further develop the MAESTRO MRD test for clinical use.

DNA 116

DNA Medical Schools Treatment Therapies 116

Broad Institute

AUGUST 19, 2024

This study is an important example of how understanding core metabolic requirements and functions of key bacteria can lead directly to new therapies that allow us to modify the microbiome for improved health,” said co-senior author Seth Bloom, an infectious diseases instructor at the Massachusetts General Hospital.

Hospitals 121

Hospitals Treatment Medical Schools Science 121

Broad Institute

FEBRUARY 7, 2024

It examined endothelial mechanisms unrelated to lipid metabolism (a known driver of CAD risk with effective therapies, like statins) in hopes of uncovering other mechanisms driving CAD risk for which therapies may yet be developed. “Now

Disease 105

Disease Hospitals Medical Schools Therapies 105

biobide

FEBRUARY 2, 2024

Children and adolescents lack robust preclinical models to replicate the pathologies and provide precise and targeted therapies. This is why not many Pharma companies specifically specialize in discovering and developing pediatric cancer treatments; a great example of advancing new therapies for childhood cancer is the biotech Oncoheroes.

Disease 59

Disease Medical Schools Pharma Companies Clinical Trials 59

Broad Institute

JANUARY 25, 2024

“We’ve come to realize recently that there is a lot more information that we can get from our retina images than we thought was possible,” says senior author Nazlee Zebardast, director of glaucoma imaging at Mass Eye and Ear and an assistant professor of ophthalmology at Harvard Medical School.

Disease 124

Disease Research Science Medical Schools 124

Drug Target Review

JUNE 6, 2023

We are in an era of immuno-oncology (IO) revolution with many approved therapies now available to treat a broad range of cancers. For the last several years, the field has worked to unlock the potential of IO therapies for additional tumour types, and has explored options beyond checkpoint inhibitors.

Engineering 98

Engineering Immune Response Biochemical Pharmacology Clinical Trials 98

Broad Institute

OCTOBER 4, 2023

The molecule’s dual mechanism of action — targeting both tumor and immune cells — is unique compared to other cancer immunotherapies including PD-1 drugs, and the researchers think it could explain why the molecule was so effective on its own in animal models and may not even need to be used in combination with other drugs such as anti-PD-1 therapy.

Small Molecule 128

Small Molecule Clinical Trials Trials Engineering 128

The Pharma Data

JANUARY 25, 2021

from Harvard Medical School in Boston, and colleagues developed evidence-based guidelines for the management of VWD and agreed on 12 recommendations. Connell, M.D.,

Disease 52

Disease Medical Schools Laboratories Therapies 52

The Pharma Data

SEPTEMBER 18, 2020

Promising Phase 2 data has been released at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 for Sanofi and Regeneron’s jointly-developed PD-1 inhibitor Libtayo (cemiplimab) in the treatment of locally advanced basal cell carcinoma (BCC) in patients for whom hedgehog inhibitor (HHI) therapy is not applicable.

Medical Schools 52

Medical Schools Trials Therapies Hospitals 52

Nvidia Developer: Drug Discovery

JULY 14, 2022

Drug discovery startup Insilico Medicine—alongside researchers from Harvard Medical School, Johns Hopkins School of Medicine, the Mayo Clinic, and. The five existing FDA-approved therapies for the disease are unable to halt or reverse this loss of function, which affects more than 700,000 people around the world. “The

Medical Schools 52

Medical Schools Clinical Trials FDA Approval Engineering 52

Broad Institute

OCTOBER 23, 2024

The work highlights the importance of examining the often-ignored noncoding parts of the genome when diagnosing rare genetic disorders, and also points to possible future genetic therapies that fine-tune CHASERR abundance as a means to treat CHASERR - and CHD2 -related disorders.

DNA 128

DNA RNA Disease Hospitals 128

The Pharma Data

NOVEMBER 10, 2020

from Harvard Medical School in Boston, and colleagues developed machine learning models to predict antibiotic susceptibility using electronic health record data and built a decision algorithm for recommending the narrowest possible antibiotic to which a specimen is susceptible for the treatment of uncomplicated UTI. TUESDAY, Nov.

Medical Schools 52

Medical Schools Science Therapies Trials 52

Drug Target Review

FEBRUARY 26, 2024

Regarding therapy resistant melanomas, why is the alteration of the epigenetic landscape considered significant, and what has been lacking in terms of validated targetable epigenetic mechanisms? What is remarkable here is that we show that the addition of corin to BRAFi-resistant tumour cells resensitises them to BRAFi therapies.

Therapies 59

Therapies Molecular Biology Regulations Medical Schools 59

The Pharma Data

JUNE 2, 2023

Zouboulis, President of the European Hidradenitis Suppurativa Foundation, Director of the Departments of Dermatology, Venereology, Allergology and Immunology, Städtisches Klinikum Dessau, and Founding Professor of Dermatology and Venereology at the Brandenburg Medical School, Germany.

Medical Schools 52

Medical Schools Treatment Disease Therapies 52

The Pharma Data

JANUARY 17, 2021

Ophthalmologists are physicians who have completed four years of medical school and four years of residency training. Treatments they help administer include patching therapy, prisms and convergence exercises. Danielle Natale, an optometrist at the Krieger Eye Institute in Baltimore, said in an institute news release.

Medical Schools 52

Medical Schools Doctors Treatment Disease 52

Broad Institute

JUNE 30, 2023

Typically, studying drug therapies is an expensive and time-consuming undertaking. The researchers also looked at the tool’s ability to detect changes in cellular phenotypes after exposure to drugs and small molecule compounds.

Small Molecule 105

Small Molecule Cell Based Assays Disease Assay Development 105

Drug Target Review

AUGUST 16, 2024

After medical school and residency I decided to dedicate my life to women and specialised in obstetrics and gynaecology. I graduated with my BS in physiology and later attended the University of Michigan Medical School. Biotechnology revolutionises healthcare : Biotechnology is transforming medicine and healthcare.

Medical Schools 111

Medical Schools Nurses Research Production 111

Broad Institute

JULY 26, 2022

By Stephanie Dutchen, Harvard Medical School Office of Communications and External Relations July 26, 2022 Credit: Susanna Hamilton, Broad Communications From immunity to metabolism to mental health, it seems like the gut microbiome has been linked to every aspect of human health and disease. Study after study had suggested that A.

Research 52

Research Immune Response Medical Schools Disease 52

Drug Target Review

JULY 1, 2024

Could you elaborate on the potential market size for SRP-001 and how it fits into the broader landscape of pain therapies? With a strong market entry strategy and continuous evidence generation, SRP-001 has the potential to transform pain therapy and meet the enormous unmet needs in this field. South Rampart Pharma, Inc.

Treatment 59

Treatment Clinical Trials Therapies Molecular Biology 59

The Pharma Data

MAY 17, 2021

. In a Viewpoint, Bishal Gyawali, MD, PhD, and colleagues at the Program on Regulation, Therapeutics and Law (PORTAL) research group at Harvard Medical School and Brigham & Women’s Hospital suggested improving FDA’s authority to modify drug package insert for situations such as drug repurposing and de-escalation of therapy.

Research 52

Research FDA Approval Drugs FDA 52

The Pharma Data

DECEMBER 13, 2020

Their extensive experience and proven track record in advancing innovative therapies, in addition to strong leadership skills, will help us to strengthen our portfolio and accelerate technology translation to help patients in need.”. Dr. Zhang completed his postdoctoral fellowship at Harvard Medical School/Boston Children’s Hospital.

Medical Schools 40

Medical Schools Clinical Development Therapies RNA 40

The Pharma Data

JANUARY 26, 2021

Dr. Short brings to VarmX extensive clinical development expertise, with a particular focus on rare diseases and gene therapy for haematological disorders. Short joins VarmX from Freeline Therapeutics, where he served for five years as SVP Clinical and Regulatory and later SVP Medical Science.

Clinical Development 40

Clinical Development Medical Schools Therapies Pharmaceuticals 40

The Pharma Data

NOVEMBER 22, 2020

Back in September, Vertex Pharmaceuticals and CRISPR Therapeutics – the company behind the CRISPR Cas-9 platform – announced that the European Medicines Agency (EMA) had granted Priority Medicines (PRIME) designation to CTX001, an investigational ex vivo CRISPR Cas-9 gene-edited therapy for the treatment of severe sickle cell disease.

DNA 52

DNA Medical Schools Treatment Science 52

The Pharma Data

JUNE 7, 2023

These longer-term results show the durable overall survival benefit of sacituzumab govitecan over traditional chemotherapy in pre-treated HR+/HER2- metastatic breast cancer,” said Sara Tolaney, MD, MPH, Chief of the Division of Breast Oncology at the Dana-Farber Cancer Institute, and Associate Professor of Medicine, Harvard Medical School. “At

Medical Schools 40

Medical Schools Therapies Treatment Clinical Development 40

NIH Director's Blog: Drug Development

APRIL 2, 2020

Solomon of Brigham and Women’s Hospital and Harvard Medical School, Boston, found that current evidence in humans is insufficient to support or refute claims that ACE inhibitors or ARBs may be helpful or harmful to individuals with COVID-19. In a new report in this week’s New England Journal of Medicine , a team of U.K.

Drug Development 52

Drug Development Drugs Science Medical Schools 52

The Pharma Data

APRIL 22, 2023

It also explains why some patients do not respond as well as others to anti-PD1 therapy. We know we need an increased arsenal of weapons to use against cancer and have to put it together to improve treatment outcomes,” said Professor Iyer, who is also head of the Division of Medical Sciences at NCCS. Source link: [link]

Medical Schools 40

Medical Schools Therapies Treatment Hospitals 40

The Pharma Data

JUNE 2, 2022

Novartis partnership with ASH’s Consortium on Newborn Screening in Africa (CONSA) will provide standard-of-care practices for screening and early intervention therapies at participating institutions in seven countries: Ghana, Kenya, Liberia, Nigeria, Uganda, Tanzania and Zambia.

Disease 52

Disease Medical Schools Treatment Therapies 52

On Medicine

APRIL 6, 2023

I have a background in Biomedical Engineering prior to medical school and a particular interest in global health and healthcare in resource-limited settings. I serve as a Professor of Pediatrics, Sidney Kimmel Medical School at Thomas Jefferson University and have been involved in medical education and research mentorship.

Medical Schools 52

Medical Schools Hospitals Treatment International 52

Broad Institute

AUGUST 4, 2022

This profiling could potentially help more accurately tailor prognosis and treatment of a new patient based on their particular molecular features, getting closer to precision medicine."

Bioinformatics 52

Bioinformatics Medical Schools Hospitals Treatment 52

NIH Director's Blog: Drug Discovery

DECEMBER 9, 2014

Tanzi, Massachusetts General Hospital/ Harvard Medical School Researchers want desperately to develop treatments to help the more than 5 million Americans with Alzheimer’s disease and the millions more at risk. Credit: Doo Yeon Kim and Rudolph E.

Drugs 52

Drugs Disease Hospitals Medical Schools 52

The Pharma Data

JANUARY 25, 2021

NeoVax is being studied as an additional therapy for other cancers, including later-stage ovarian and kidney cancers. . “The vaccine can induce a durable immune system response that is well-tolerated.” ” In theory, Ott said, personalized vaccines could be used for a range of cancers. SOURCES: Patrick A. 21, 2021, online.

Vaccine 52

Vaccine Immune Response Medical Schools Clinical Trials 52

The Pharma Data

DECEMBER 28, 2020

Scopus is a biopharmaceutical company whose lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers. Dr. Hofstein completed his postdoctoral training and research in the Department of Neurobiology at Harvard Medical School. Hofstein received his B.Sc.

Pharmaceuticals 52

Pharmaceuticals Pharmaceutical Companies Government Therapies 52

Broad Institute

JUNE 21, 2023

Typically, studying drug therapies is an expensive and time-consuming undertaking. By makenziekohler June 23, 2023 Related Claussnitzer Lab first paragraph The field of microscopy has grown immensely over the last fifty years in its ability to extract both quantitative and qualitative data from microscopic images.

Small Molecule 52

Small Molecule Cell Based Assays Medical Schools Disease 52

KIF1A

MAY 31, 2024

In addition to her role as Chief of the Department of Pediatrics, Dr. Chung serves as the Mary Ellen Avery Professor at Harvard Medical School (HMS), and President of the Children’s Hospital Pediatric Associates. Chung Chief of the Department of Pediatrics. Dr. Markus Terrey described this approach during his conference talk.

Treatment 52

Treatment Small Molecule International Research 52

The Pharma Data

DECEMBER 15, 2020

In late 2020, the effort received $200,000 in seed funding from the Baker Department of Cardiometabolic Health at the University of Melbourne’s medical school. The clinical responses were sustained by maintenance therapy with belimumab, an antibody to B-cell activating factor. Warm Autoimmune Hemolytic Anemia.

Disease 52

Disease Clinical Trials Small Molecule Trials 52

The Pharma Data

MARCH 13, 2021

. “A key insight of the results from the TRAILBLAZER-ALZ study is that donanemab not only significantly reduced the amount of amyloid deposition in these patients but also slowed the clinical progression of the disease suggesting that this could be a disease-modifying therapy. Salloway, M.S.,

Disease 40

Disease Trials Treatment Medical Schools 40